A comprehensive laboratory reference for reconstituting lyophilised research peptides: solvent selection, aseptic technique, concentration calculations, storage conditions, and compound-specific stability data.
Lyophilisation (freeze-drying) is the gold standard for long-term preservation of peptides and proteins. The process removes water by sublimation under vacuum, yielding a stable amorphous powder that resists enzymatic degradation, oxidation, and hydrolysis.
Choosing the correct solvent is the single most important decision in the reconstitution process. The wrong solvent can cause precipitation, aggregation, or chemical modification of the peptide.
| Solvent | Composition | Best For | Shelf Life (2–8°C) | Notes |
|---|---|---|---|---|
| Bacteriostatic Water (BAC) | Water for injection + 0.9% benzyl alcohol | Most research peptides (BPC-157, Semax, Ipamorelin, TB-500, CJC-1295, GHK-Cu) | 28–30 days | Bacteriostatic agent inhibits microbial growth. First choice for multi-dose vials. |
| Sterile Saline | 0.9% NaCl in WFI | Immediate-use preparations; pH-sensitive peptides | 5–7 days | Physiological ionic strength. Good for in vivo studies. No preservative. |
| Dilute Acetic Acid | 0.1–1% glacial acetic acid in sterile water | Hydrophobic / basic peptides: HGH Frag (176-191), GHRP-2, GHRP-6, Sermorelin | 7–14 days | Lowers pH → protonates basic residues → improves aqueous solubility. Dilute before use in cell studies. |
| DMSO (diluted) | ≤10% in sterile water or PBS | Highly hydrophobic cyclic peptides; in vitro cell culture only | 30 days (−20°C) | Do NOT use for in vivo models. Cytotoxic at >0.5% in culture. Dissolve in DMSO first, then dilute. |
| PBS (pH 7.4) | Phosphate-buffered saline | Cell culture assays, receptor binding studies | 7–14 days | Maintain physiological pH. Check compatibility — phosphate can precipitate with divalent cations. |
Contamination is the primary cause of reconstituted peptide degradation and experimental failure. Strict aseptic technique protects both the compound and the validity of your research data.
Never use tap water, distilled water, or sterile water for injection (WFI) as a long-term vehicle. WFI contains no preservatives and supports rapid microbial growth at refrigerator temperatures. Use bacteriostatic water for any multi-dose preparation.
Follow this sequence precisely for every reconstitution. Deviations, particularly rushing dissolution, are the most common source of aggregation and experimental error.
Gather: peptide vial, sterile solvent (BAC water), appropriate syringe (1 mL insulin syringe or luer-lock), sterile needles (23–25G), 70% IPA swabs, and label materials. Confirm the peptide vial identity, batch, and that it is still within valid storage parameters (inspect seal integrity, powder appearance).
Remove the peptide vial from cold storage and allow it to reach room temperature (15–25°C) before opening. This prevents condensation from forming inside the vial when punctured, which can introduce contaminants and compromise the lyophilised structure. Allow 15–20 minutes for -20°C stored vials.
Wipe the rubber septum of both the solvent vial and the peptide vial with a fresh 70% IPA swab using a single, outward spiral motion. Allow 30 seconds to air-dry. Do not blow on or wave the swab to speed drying — this recontaminates the surface.
Using a fresh, sterile syringe and needle, draw the calculated volume of bacteriostatic water (see Section 5). Expel any air bubbles by pointing the needle upward and gently tapping and pressing the plunger. Swap to a fresh needle before proceeding to avoid particulate carry-over.
Insert the needle into the peptide vial septum at a shallow angle and direct the needle tip toward the inner glass wall. Slowly depress the plunger so the solvent runs down the inner wall rather than directly onto the lyophilised cake. This prevents forceful disruption of the peptide matrix and reduces foaming. Inject the full volume over 30–60 seconds.
Set the vial down and allow the solvent to absorb into the cake for 60–120 seconds. Most well-lyophilised peptides will begin dissolving immediately. Then gently swirl the vial (circular motion) until the solution is clear and uniform. Avoid inversion, shaking, or vortexing — these cause aggregation at the air-water interface.
Hold the vial against a bright background (white paper or lightbox). The solution should be clear and colourless (or faintly yellow for some peptides). Particulates, cloudiness, or sediment indicate incomplete dissolution, aggregation, or contamination — do not proceed; see Section 8 (Troubleshooting).
Label the vial with: compound name, batch, concentration (mcg/mL), reconstitution date, expiry date, and solvent used. Wrap in foil if photosensitive. Store immediately at 2–8°C. Do not leave at room temperature for extended periods.
Accurate concentration calculation is critical for dose–response linearity and inter-experiment reproducibility. All AVREA vials contain precisely weighed lyophilised peptide; the mass stated on the label is the basis for your calculation.
| Vial Size | Solvent Volume Added | Resulting Concentration | 200 mcg Dose Volume | 500 mcg Dose Volume |
|---|---|---|---|---|
| 1 mg (1,000 mcg) | 1 mL | 1,000 mcg/mL | 0.20 mL (200 µL) | 0.50 mL (500 µL) |
| 2 mg (2,000 mcg) | 1 mL | 2,000 mcg/mL | 0.10 mL (100 µL) | 0.25 mL (250 µL) |
| 2 mg (2,000 mcg) | 2 mL | 1,000 mcg/mL | 0.20 mL (200 µL) | 0.50 mL (500 µL) |
| 5 mg (5,000 mcg) | 2 mL | 2,500 mcg/mL | 0.08 mL (80 µL) | 0.20 mL (200 µL) |
| 5 mg (5,000 mcg) | 5 mL | 1,000 mcg/mL | 0.20 mL (200 µL) | 0.50 mL (500 µL) |
| 10 mg (10,000 mcg) | 5 mL | 2,000 mcg/mL | 0.10 mL (100 µL) | 0.25 mL (250 µL) |
Peptide stability is determined by: temperature, pH, light exposure, oxygen levels, ionic strength, and the presence of preservatives. Adhering to storage guidelines preserves purity and prevents aggregation.
| State | Temperature | Light | Max Duration | Container |
|---|---|---|---|---|
| Lyophilised (unsealed) | −20°C | Protected | 24–36 months | Original sealed vial, argon-purged |
| Lyophilised (short-term) | 2–8°C | Protected | 12 months | Desiccant-sealed container |
| Reconstituted — BAC water | 2–8°C | Protected | 28–30 days | Amber glass vial |
| Reconstituted — saline/water | 2–8°C | Protected | 5–7 days | Sealed sterile vial |
| Reconstituted — aliquots (frozen) | −20°C | N/A | 3–6 months | Sealed LDPE vials, freeze once only |
*Retatrutide's C20 fatty diacid modification provides superior aqueous stability vs unmodified peptides.
Avoid freeze-thaw cycles. Each cycle causes ice crystal formation that shears peptide aggregates and disrupts tertiary structure. If long-term storage is needed after reconstitution, aliquot into single-use volumes before the first freeze. Thaw only what you will use that day.
Preferred solvent: Bacteriostatic water. BPC-157 is freely soluble in aqueous solutions at physiological pH. Dissolves rapidly (typically <60 seconds). Standard concentration: For a 5 mg vial, 2 mL BAC water → 2,500 mcg/mL stock. Photosensitivity: Moderate. Wrap vial in foil after reconstitution. Special notes: BPC-157 is also soluble in dilute saline and PBS. For oral gavage studies in rodents, can be dissolved in sterile saline at any concentration. The peptide is stable over pH 4–8.
→ Full BPC-157 compound guidePreferred solvent: Bacteriostatic water. Retatrutide's C20 fatty diacid modification (for albumin binding) makes it less soluble than short-chain peptides. Allow longer dissolution time (2–5 minutes). Warm BAC water slightly (to 25–30°C) if dissolution is slow — do not exceed 37°C. Standard concentration: 2 mg vial + 1 mL BAC water → 2,000 mcg/mL. Fatty acid modification: The palmitoyl chain can cause mild opalescence at high concentrations — this is normal and not indicative of aggregation. Dilute 1:10 in saline for use if opalescence concerns experiment design.
→ Full Retatrutide compound guidePreferred solvent: Bacteriostatic water or sterile saline. Semax is highly water-soluble and dissolves within seconds. Key concern — Methionine oxidation: The N-terminal methionine residue is susceptible to oxidation by dissolved oxygen. Use freshly opened solvent, avoid vigorously shaking, and protect from light. For studies where Met-1 oxidation could confound results (e.g., receptor binding assays), use deoxygenated solvent or add 1 mM ascorbic acid as antioxidant. Intranasal studies: For iN administration in rodents, use isotonic saline (0.9% NaCl) to minimise nasal mucosal irritation. Final iN concentration typically 1–10 mg/mL for 5–10 µL nostril volumes.
→ Full Semax compound guidePreferred solvent: 0.1–0.5% acetic acid in sterile water, or bacteriostatic water. These hexapeptide secretagogues are moderately hydrophobic and dissolve best at slightly acidic pH due to protonation of His residues. If using BAC water and dissolution is incomplete after 3 minutes, add a drop of glacial acetic acid directly to the vial (adjust to ~0.1% final). Standard concentration: 2 mg vial + 2 mL BAC water → 1,000 mcg/mL. Note: Do not co-administer in the same syringe with insulin — potential interaction. Always use separate syringes for combination experiments.
Preferred solvent: Sterile water or bacteriostatic water. GHK-Cu is supplied as the copper complex (GHK-Cu²⁺) and dissolves to a clear blue-green solution — this colour is normal and confirms copper coordination. Compatibility: Do not combine with EDTA-containing buffers (chelation), phosphate buffers at high concentration (copper precipitation), or alkaline pH (>8). Avoid metal-contaminated glassware; use polypropylene tubes for storage. Stability: Shorter stability window than most peptides — use within 14 days at 2–8°C. The Cu²⁺ coordination can be disrupted by oxidation; store in dark conditions.
| Problem | Likely Cause | Resolution |
|---|---|---|
| Peptide won't dissolve | Wrong solvent; highly hydrophobic peptide; cold peptide | Switch to dilute acetic acid (0.1%). Ensure vial is at room temp. Try warming solvent to 25°C. Swirl gently for 5 min. |
| Cloudy solution / white particulates | Aggregation; incomplete dissolution; contamination | Swirl gently (do not vortex). If persists, pass through 0.22 µm sterile filter. Discard if contamination suspected. |
| Solution turns yellow/brown | Oxidation of Trp, Tyr, or Met residues; light exposure | Discard — oxidation compromises peptide integrity. Use freshly degassed solvent and amber vials for future preparations. |
| Vial appears empty (no powder) | Lyophilisation collapse; extreme humidity exposure; electrostatic adhesion | The peptide may be as a thin, invisible film on the vial walls. Add solvent as normal — dissolve and verify with spectrophotometry at 214 nm or 280 nm if available. |
| Foam on surface after adding solvent | Too-rapid injection; shaking | Allow foam to settle (5–10 min). Do not draw while foam is present. Swirl gently rather than agitating. Inject more slowly next time. |
| Gel-like consistency | Self-assembling peptide (e.g., RADA-16); concentration too high | Dilute 1:2 with sterile water. Some self-assembling peptides require sonication (3× 30 sec pulses, probe sonicator). |
Every compound batch-tested by third-party ISO-accredited laboratory. Full COA provided on request. For qualified research institutions only.
Browse Peptide Catalog → Research FAQ